Provided by Tiger Trade Technology Pte. Ltd.

TriSalus Life Sciences Inc.

5.11
-0.1600-3.04%
Volume:86.91K
Turnover:445.84K
Market Cap:313.28M
PE:-3.84
High:5.30
Open:5.30
Low:5.03
Close:5.27
52wk High:7.95
52wk Low:2.20
Shares:61.31M
Float Shares:43.63M
Volume Ratio:0.77
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.8389
ROE:-496.21%
ROA:-36.75%
PB:47.83
PE(LYR):-2.78

Loading ...

TriSalus Life Sciences holds annual stockholder meeting

Reuters
·
May 15

Maxim Group Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)

TIPRANKS
·
May 14

TriSalus Life Sciences Is Maintained at Buy by Lake Street

Dow Jones
·
May 14

Top Midday Decliners

MT Newswires Live
·
May 14

Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results

Benzinga Earnings
·
May 14

TriSalus Life Sciences price target lowered to $8 from $10 at Lake Street

TIPRANKS
·
May 13

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM

Reuters
·
May 13

TriSalus Life Sciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

TriSalus Life Sciences Q1 EPS $0.03 Beats $(0.16) Estimate, Sales $8.899M Miss $10.440M Estimate

Benzinga Earnings
·
May 13

TriSalus swings to Q1 FY26 profit of $1.5 million; revenue falls 2.9% to $8.9 million

Reuters
·
May 13

TriSalus Life Sciences Inc - Revises 2026 Revenue Guidance to $54 Mln-$57 Mln

THOMSON REUTERS
·
May 13

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

THOMSON REUTERS
·
May 13

TriSalus Life Sciences Q1 Pretax Profit USD 1.543 Million

THOMSON REUTERS
·
May 13

TriSalus announces journal publication of PEDD study

TIPRANKS
·
May 13

TriSalus PEDD real-world study shows $7,734 charge avoidance, improved outcomes in liver cancers

Reuters
·
May 12

TriSalus Life Sciences Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 09

Lake Street Remains a Buy on TriSalus Life Sciences (TLSI)

TIPRANKS
·
May 05

TriSalus launches PREDICTT trial testing pressure-enabled delivery in Y90 liver tumor therapy

Reuters
·
May 05

TriSalus Life Sciences Announces Launch of Predictt Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

THOMSON REUTERS
·
May 05

TriSalus Chief of Clinical Operations Devlin to retire Oct. 1

Reuters
·
Apr 30